Investors

Shareholder Tools

 

Overview

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The Company’s lead product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine designed to provide more rapid and increased protection with fewer doses than current licensed vaccines. For more information visit www.dynavax.com.

Recent Press Releases

Feb 8, 2010
Dynavax Initiates Large-Scale Phase 3 Trial of HEPLISAV(TM)

Jan 26, 2010
Dynavax Reports Positive Phase 1b Data for SD-101 in Chronic Hepatitis C Infection

View all releases »

E-Delivery of Stockholder Communications

Beneficial stockholders

Registered stockholders

Annual Report and Proxy

10-K

Proxy